cell_id,prompt,answer,output_70
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JW-7-24-1. The drug SMILES structure is COC1=CC(=CC(=C1)C2=CC3=C4C(=CN=C3C=C2)C=CC(=O)N4C5=CC(=C(C=C5)N6CCNCC6)C(F)(F)F)OC. Drug target is LCK. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug JW-7-24-1 is a potent and selective LCK inhibitor. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are not directly related to the drug target LCK, and therefore, the drug is expected to be effective against the cell line. Additionally, the drug has been shown to be effective against various types of cancer, including those with mutations in the PI3K/Akt pathway, which is downstream of LCK. Therefore, the drug is likely to be sensitive to the cell line with these mutations."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KIN001-260. The drug SMILES structure is C1CC1COC2=CC=CC(=O)C2=C3C=C(C(=C(N3)N)C#N)C4CCNCC4. Drug target is CDC7. Drug target pathway is DNA replication.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug KIN001-260 targets CDC7, which is involved in DNA replication. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not directly affect the DNA replication pathway. Therefore, the drug should still be effective in inhibiting CDC7 and preventing DNA replication in this cell line, making it sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NSC-87877. The drug SMILES structure is C1=CC2=C(C(=O)C(=NNC3=CC4=C(C=C3)C=C(C=C4)S(=O)(=O)O)C=C2S(=O)(=O)O)N=C1. Drug target is SHP-1 (PTPN6), SHP-2 (PTPN11). Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug NSC-87877 is a SHP-1 and SHP-2 inhibitor, which targets the PI3K/Akt signaling pathway. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, are all involved in the PI3K/Akt signaling pathway. Inhibition of SHP-1 and SHP-2 by NSC-87877 would likely disrupt the regulation of the PI3K/Akt pathway, leading to increased sensitivity of the cell line to the drug. Therefore, the drug sensitivity of NSC-87877 on the cell line with these mutations is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PLX-4720. The drug SMILES structure is CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)Cl)F. Drug target is BRAF. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug PLX-4720 is a BRAF inhibitor that targets the BRAF protein in the ERK MAPK signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. However, none of these mutations are in the BRAF gene or in genes that are directly downstream of BRAF in the ERK MAPK signaling pathway. Therefore, it is likely that the cell line is still dependent on the BRAF protein for its proliferation and survival, and inhibition of BRAF by PLX-4720 would be effective in inhibiting the cell line's growth."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ERK5-IN-1. The drug SMILES structure is CCOC1=C(C=CC(=C1)C(=O)N2CCC(CC2)N3CCN(CC3)C)NC4=NC=C5C(=N4)N(C6=CC=CC=C6C(=O)N5C)C7CCCC7. Drug target is ERK5, BET. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug ERK5-IN-1 is a BET inhibitor, which targets the ERK5 pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. Among these mutations, NOTCH1 and NOTCH3 are upstream regulators of the ERK5 pathway, and their mutations may lead to increased activity of the ERK5 pathway. Additionally, PIK3R1 and PPP2R1A are downstream targets of the ERK5 pathway, and their mutations may also contribute to increased activity of the ERK5 pathway. Therefore, inhibition of the ERK5 pathway by ERK5-IN-1 may be particularly effective in this cell line due to the accumulated genetic alterations that promote ERK5 signaling."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VX-11E. The drug SMILES structure is CC1=CN=C(NC2=C(Cl)C=C(F)C=C2)N=C1C3=CNC(C(N[C@@H](C4=CC(Cl)=CC=C4)CO)=O)=C3. Drug target is ERK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug VX-11E targets the ERK2 protein, which is downstream of the NOTCH1 and NOTCH3 receptors in the NOTCH signaling pathway. The cell line has mutations in NOTCH1 and NOTCH3, which are upstream of ERK2 and could potentially activate the ERK2 protein. Therefore, the drug VX-11E may still be effective in inhibiting the activity of ERK2 in this cell line, despite the presence of these mutations. Additionally, the cell line has mutations in genes involved in other signaling pathways, such as PIK3R1 and PPP2R1A, which may also contribute to the sensitivity of the cell line to VX-11E. Overall, the presence of these mutations suggests that the cell line may still be sensitive to the drug VX-11E."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TGX-221. The drug SMILES structure is CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3)N4CCOCC4. Drug target is PI3Kbeta. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug TGX-221 is a PI3Kbeta inhibitor, and the cell line has a mutation in the PIK3R1 gene, which encodes the regulatory subunit of PI3K. This mutation is likely to increase the activity of PI3K, making the cell line more dependent on PI3K signaling. Inhibition of PI3Kbeta by TGX-221 would therefore be more effective in inhibiting the PI3K/MTOR signaling pathway in this cell line, leading to increased sensitivity to the drug. Additionally, the cell line has mutations in genes involved in other signaling pathways (NOTCH1, NOTCH3, TSC2, WHSC1L1), which may also contribute to increased sensitivity to TGX-221."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DASATINIB. The drug SMILES structure is CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=NC(=NC(=C3)N4CCN(CC4)CCO)C. Drug target is ABL, SRC, Ephrins, PDGFR, KIT. Drug target pathway is RTK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: DASATINIB is a tyrosine kinase inhibitor that targets ABL, SRC, Ephrins, PDGFR, and KIT, which are all involved in the RTK signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. Among these mutations, NOTCH1 and NOTCH3 are upstream regulators of the RTK signaling pathway, and their mutations may increase the activity of this pathway. PIK3R1 and PPP2R1A are regulators of the PI3K/AKT signaling pathway, which is downstream of the RTK signaling pathway. TP53 is a tumor suppressor gene that regulates various cellular processes, including cell cycle and apoptosis. TSC2 is a negative regulator of the mTOR signaling pathway, which is downstream of the RTK signaling pathway. WHSC1L1 is a histone methyltransferase that may play a role in regulating gene expression.

Given the mutations in the cell line, it is likely that the RTK signaling pathway is activated, and DASATINIB, as a tyrosine kinase inhibitor, would inhibit the activity of the mutated RTKs, leading to inhibition of downstream signaling pathways. Therefore, the cell line with these mutations would be sensitive to DASATINIB."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ZM-447439. The drug SMILES structure is COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4)OCCCN5CCOCC5. Drug target is AURKA, AURKB. Drug target pathway is Mitosis.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug ZM-447439 targets AURKA and AURKB, which are involved in the mitosis pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations do not directly affect the mitosis pathway, and therefore, the drug should still be effective in inhibiting the AURKA and AURKB proteins. Therefore, the drug sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CGP-082996. The drug SMILES structure is CCNC1=CC(=NC(=N1)NC2=CC3=C(C=C2)N(C=C3)CC4=CC=CC=C4)NC5CCC(CC5)O. Drug target is CDK4. Drug target pathway is Cell cycle.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug CGP-082996 is a CDK4 inhibitor, which targets the cell cycle pathway. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not directly affect the CDK4 pathway. Therefore, the drug should still be effective in inhibiting CDK4 and preventing cell cycle progression, making the cell line sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is UPROSERTIB. The drug SMILES structure is CN1C(=C(C=N1)Cl)C2=C(OC(=C2)C(=O)N[C@@H](CC3=CC(=C(C=C3)F)F)CN)Cl. Drug target is AKT1, AKT2, AKT3. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug UPROSERTIB is an inhibitor of AKT1, AKT2, and AKT3, which are downstream targets of the PI3K/MTOR signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. Among these genes, NOTCH1 and NOTCH3 are upstream regulators of the PI3K/MTOR pathway, and their mutations may lead to the activation of this pathway. Additionally, PIK3R1 and PPP2R1A are regulators of the PI3K/MTOR pathway, and their mutations may also activate this pathway. TP53 is a tumor suppressor gene that regulates various cellular processes, including cell cycle and apoptosis, and its mutation may lead to uncontrolled cell growth. TSC2 is a negative regulator of the mTOR pathway, and its mutation may activate the mTOR pathway. WHSC1L1 is a gene that encodes a protein involved in the regulation of histone modification and chromatin remodeling, and its mutation may also activate the PI3K/MTOR pathway. Considering the drug target and the cell line mutations, it is likely that the cell line is sensitive to UPROSERTIB, as the drug can effectively inhibit the activated PI3K/MTOR pathway."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DORAMAPIMOD. The drug SMILES structure is CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCCN5CCOCC5. Drug target is p38, JNK2. Drug target pathway is JNK and p38 signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug DORAMAPIMOD is a p38 and JNK2 inhibitor. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are involved in various cellular processes, including cell proliferation, differentiation, and survival. However, none of these mutations directly affect the p38 or JNK signaling pathways, which are the primary targets of DORAMAPIMOD. Therefore, the drug is likely to be effective in inhibiting the p38 and JNK signaling pathways in this cell line, leading to sensitive drug sensitivity."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AST-1306. The drug SMILES structure is C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=C(C=C3)OCC4=CC(=CC=C4)F)Cl. Drug target is EGFR, ERBB4. Drug target pathway is RTK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug AST-1306 is a pan-RTK inhibitor targeting EGFR, ERBB4, and other RTKs. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are involved in various cellular processes, including cell proliferation, differentiation, and survival. However, none of these mutations directly affect the EGFR or ERBB4 pathway, which is the primary target of AST-1306. Therefore, the drug is likely to be effective in inhibiting RTK signaling in this cell line, leading to sensitive drug sensitivity."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WIKI4. The drug SMILES structure is COC1=CC=C(C=C1)N2C(=NN=C2SCCCN3C(=O)C4=CC=CC5=C4C(=CC=C5)C3=O)C6=CC=NC=C6. Drug target is TNKS1, TNKS2. Drug target pathway is WNT signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug WIKI4 targets the TNKS1 and TNKS2 proteins, which are involved in the WNT signaling pathway. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not affect the WNT signaling pathway or the target proteins of WIKI4. Therefore, the drug is expected to be effective against the cell line, and the sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is OLAPARIB. The drug SMILES structure is C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F. Drug target is PARP1, PARP2. Drug target pathway is Genome integrity.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: Olaparib is a PARP inhibitor that targets PARP1 and PARP2, which are involved in DNA repair and genomic stability. The cell line has mutations in genes involved in the PI3K/AKT/mTOR pathway (PIK3R1, PPP2R1A), the Notch signaling pathway (NOTCH1, NOTCH3), and the TSC complex (TSC2), which can lead to increased activation of PI3K/AKT/mTOR and Notch signaling. Additionally, the cell line has a mutation in TP53, which can lead to increased resistance to chemotherapy. However, the presence of a mutation in WHSC1L1, which is involved in the splicing of PARP1 mRNA, may also contribute to increased sensitivity to Olaparib. Overall, the presence of these mutations may increase the reliance on PARP1 and PARP2 for DNA repair, making the cell line more sensitive to Olaparib."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AGI-6780. The drug SMILES structure is C1CC1NS(=O)(=O)C2=CC(=C(C=C2)C3=CSC=C3)NC(=O)NC4=CC=CC(=C4)C(F)(F)F. Drug target is IDH2(R140Q). Drug target pathway is Metabolism.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug AGI-6780 is a potent inhibitor of IDH2, which is a key enzyme in the citric acid cycle. The R140Q mutation in IDH2 has been shown to result in a gain-of-function activity, leading to increased production of 2-hydroxyglutarate (2HG), a metabolite that plays a critical role in various cellular processes. Inhibition of IDH2 by AGI-6780 would reduce the levels of 2HG, which could potentially inhibit the growth of cells that rely on this metabolite.

The presence of mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 does not directly affect the activity of IDH2 or the sensitivity of the cell line to AGI-6780. Therefore, the cell line with these mutations would still be sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CUDC-101. The drug SMILES structure is COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCCCCC(=O)NO. Drug target is HDAC1-10, EGFR, ERBB2. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: CUDC-101 is a pan-HDAC inhibitor that targets HDAC1-10, EGFR, and ERBB2. The drug works by inhibiting the activity of histone deacetylases, which are enzymes that play a role in regulating gene expression by removing acetyl groups from histones, leading to the condensation of chromatin and the repression of gene transcription. The drug also inhibits the activity of EGFR and ERBB2, which are receptors that play a role in cell signaling pathways involved in cell growth and survival.

The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are known to be associated with cancer and may affect the expression of genes involved in cell growth and survival. However, none of these mutations are known to affect the activity of HDAC1-10, EGFR, or ERBB2, which are the primary targets of CUDC-101. Therefore, it is likely that the drug will still be effective in inhibiting the activity of these targets in the cell line, leading to sensitive drug sensitivity."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SB-505124. The drug SMILES structure is CC1=NC(=CC=C1)C2=C(N=C(N2)C(C)(C)C)C3=CC4=C(C=C3)OCO4. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug SB-505124 is a small molecule inhibitor of the Notch signaling pathway, which is involved in various cellular processes, including cell fate determination, cell proliferation, and angiogenesis. The NOTCH1 and NOTCH3 mutations in the cell line suggest that the Notch signaling pathway is activated, and the drug is likely to inhibit the activity of the Notch receptors, leading to reduced cell proliferation and increased sensitivity to the drug. Additionally, the PIK3R1 and PPP2R1A mutations may also contribute to the sensitivity of the cell line to the drug, as they are involved in downstream signaling pathways that interact with the Notch pathway. The TP53, TSC2, and WHSC1L1 mutations may also play a role in the drug sensitivity, but their exact contributions are unclear. Overall, the combination of these mutations suggests that the cell line is likely to be sensitive to the drug SB-505124."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CP-724714. The drug SMILES structure is CC1=NC=C(C=C1)OC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)C=CCNC(=O)COC)C. Drug target is ERBB2. Drug target pathway is EGFR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug CP-724714 is a tyrosine kinase inhibitor that targets the ERBB2 protein. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. These mutations are not directly related to the ERBB2 pathway, which suggests that the drug should still be effective in inhibiting the ERBB2 protein. Therefore, the drug sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD8931. The drug SMILES structure is CNC(=O)CN1CCC(CC1)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC. Drug target is EGFR, ERBB2, ERBB3. Drug target pathway is RTK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug AZD8931 is a pan-EGFR inhibitor that targets the EGFR, ERBB2, and ERBB3 receptors. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. However, none of these mutations are known to confer resistance to EGFR inhibitors. In fact, some of these mutations, such as TP53 and PIK3R1, have been associated with increased sensitivity to EGFR inhibitors. Therefore, based on the available information, it is likely that the cell line with these mutations would be sensitive to AZD8931."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is IMATINIB. The drug SMILES structure is CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5. Drug target is ABL, KIT, PDGFR. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug IMATINIB is a tyrosine kinase inhibitor that targets ABL, KIT, and PDGFR. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations do not affect the drug target or its pathway directly. Therefore, the drug is expected to be effective against the cell line, and the sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LGK-974. The drug SMILES structure is CC1=CC(=CN=C1C2=CC(=NC=C2)C)CC(=O)NC3=NC=C(C=C3)C4=NC=CN=C4. Drug target is PORCN. Drug target pathway is WNT signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug LGK-974 is a PORCN inhibitor, which targets the WNT signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are known to activate the WNT signaling pathway, which would increase the sensitivity of the cell line to LGK-974. Therefore, the drug sensitivity of LGK-974 on this cell line is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NVP-BHG712. The drug SMILES structure is CC1=C(C=C(C=C1)C(=O)NC2=CC=CC(=C2)C(F)(F)F)NC3=NC(=NC4=C3C=NN4C)C5=CN=CC=C5. Drug target is EPHB4, RAF, SRC, ABL. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug NVP-BHG712 is a pan-RAF inhibitor that targets RAF, SRC, and ABL kinases. The cell line has a mutation in PIK3R1, which is a negative regulator of the PI3K/AKT pathway. The PI3K/AKT pathway is downstream of the RAF/MEK/ERK pathway, which is targeted by NVP-BHG712. Therefore, the mutation in PIK3R1 is likely to increase the sensitivity of the cell line to NVP-BHG712. Additionally, the cell line has a mutation in TP53, which is a tumor suppressor gene that regulates cell cycle and apoptosis. The mutation in TP53 may also contribute to increased sensitivity to NVP-BHG712. Overall, based on the drug target and the mutations present in the cell line, it is likely that NVP-BHG712 will be effective in inhibiting the growth of this cell line."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ZG-10. The drug SMILES structure is O=C(C1=CC=C(NC(C=CCN(C)C)=O)C=C1)NC2=CC(NC3=NC(C4=CC=CN=C4)=CC=N3)=CC=C2. Drug target is JNK1. Drug target pathway is JNK and p38 signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug ZG-10 targets JNK1, which is downstream of the NOTCH signaling pathway. The cell line has mutations in NOTCH1 and NOTCH3, which are upstream of JNK1. These mutations are likely to activate the NOTCH signaling pathway, leading to increased activity of JNK1. Therefore, the drug ZG-10 is likely to be effective in inhibiting JNK1 activity in this cell line, making it sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CX-5461. The drug SMILES structure is CC1=CN=C(C=N1)CNC(=O)C2=C3N(C4=CC=CC=C4S3)C5=C(C2=O)C=CC(=N5)N6CCCN(CC6)C. Drug target is RNA Polymerase 1. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug CX-5461 is a small molecule inhibitor of RNA polymerase 1, which is essential for transcription of DNA into RNA. The drug targets the RNA polymerase 1 enzyme, which is overexpressed in many cancer cell lines, including those with the mutations present in this cell line. The mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 do not affect the drug's mechanism of action or its target, and therefore, the drug is likely to be effective against this cell line."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ERLOTINIB. The drug SMILES structure is COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC. Drug target is EGFR. Drug target pathway is EGFR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug ERLOTINIB is a tyrosine kinase inhibitor that targets the EGFR protein. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not directly affect the EGFR protein or its downstream signaling pathways. Therefore, the drug should still be effective in inhibiting the EGFR protein and its signaling pathways, making the cell line sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CMK. The drug SMILES structure is CC1=CC=C(C=C1)C2=C(N(C3=NC=NC(=C23)N)CCCO)C(=O)CCl. Drug target is RSK2. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: CMK is a small molecule inhibitor of RSK2, which is a downstream target of the PI3K/AKT pathway. The cell line has mutations in PIK3R1 and PPP2R1A, which are upstream regulators of the PI3K/AKT pathway. These mutations may lead to increased activity of the PI3K/AKT pathway, making the cell line more sensitive to inhibition of RSK2 by CMK. Additionally, the cell line has a mutation in TP53, which is a tumor suppressor gene that regulates cell cycle and apoptosis. The mutation in TP53 may also contribute to increased sensitivity to CMK. Therefore, based on the drug target and the mutations present in the cell line, it is predicted that the cell line will be sensitive to CMK."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LIMK1 INHIBITOR BMS4. The drug SMILES structure is CCNC(=O)NC1=NC=C(S1)C2=CC(=NC(=N2)C3=NC=CN=C3)C4=C(C=C(C=C4C)OC)C. Drug target is LIMK1. Drug target pathway is Cytoskeleton.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug BMS4 is an inhibitor of LIMK1, which is a key regulator of the cytoskeleton pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. These mutations are known to affect the cytoskeleton pathway and may increase the reliance of the cells on the LIMK1 pathway for survival. Therefore, inhibition of LIMK1 by BMS4 may be particularly effective in targeting these cells. Additionally, the drug's mechanism of action, which involves inhibiting the activity of LIMK1, is likely to be effective against cells with these mutations."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AT13148. The drug SMILES structure is C1=CC(=CC=C1C2=CNN=C2)[C@@](CN)(C3=CC=C(C=C3)Cl)O. Drug target is AKT1. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug AT13148 is an inhibitor of AKT1, which is a key protein in the PI3K/MTOR signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are known to activate the PI3K/MTOR pathway, which would make the cell line more sensitive to the drug. In addition, the drug's mechanism of action is to inhibit the activation of AKT1, which is already activated in the cell line due to the mutations, making it more sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FTI-277. The drug SMILES structure is COC(=O)[C@H](CCSC)NC(=O)C1=C(C=C(C=C1)NC[C@H](CS)N)C2=CC=CC=C2. Drug target is Farnesyl-transferase (FNTA). Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug FTI-277 is a farnesyl-transferase inhibitor that targets the FNTA enzyme. The drug works by inhibiting the farnesylation of proteins, which is a post-translational modification that plays a crucial role in various cellular processes, including cell signaling and protein-protein interactions.

The cell line with the given mutations, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1, is sensitive to FTI-277 because the drug targets a downstream effector of the NOTCH signaling pathway, which is affected by the NOTCH1 and NOTCH3 mutations. The PIK3R1 and PPP2R1A mutations also play a role in the regulation of the PI3K/Akt signaling pathway, which is connected to the NOTCH pathway. The TP53 mutation may also contribute to the sensitivity of the cell line to FTI-277, as TP53 is a tumor suppressor gene that regulates various cellular processes, including cell cycle and apoptosis.

Therefore, the combination of these mutations in the cell line suggests that FTI-277 may be effective in inhibiting the farnesylation of proteins involved in the NOTCH signaling pathway and other cellular processes, leading to the inhibition of cell growth and proliferation."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NVP-ADW742. The drug SMILES structure is C1CCN(C1)CC2CC(C2)N3C=C(C4=C3N=CN=C4N)C5=CC(=CC=C5)OCC6=CC=CC=C6. Drug target is IGF1R. Drug target pathway is IGF1R signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug NVP-ADW742 is an IGF1R inhibitor, which targets the IGF1R signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. Among these genes, TP53 is a tumor suppressor gene, and its mutation can lead to the development of cancer. However, the other genes are not directly related to the IGF1R signaling pathway. Therefore, the drug is expected to be effective in inhibiting the IGF1R signaling pathway and sensitive to the cell line with these mutations."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ENZASTAURIN. The drug SMILES structure is CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7. Drug target is PKCB. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: Enzastaurin is a PKCβ inhibitor, which targets the PKCB protein. The cell line has a mutation in the TP53 gene, which is a tumor suppressor gene that regulates cell growth and division. The mutation in TP53 can lead to uncontrolled cell growth and division, making the cell line more sensitive to the inhibition of PKCβ by enzastaurin. Additionally, the cell line has a mutation in the PIK3R1 gene, which encodes a protein that regulates the PI3K/Akt signaling pathway. The mutation in PIK3R1 can activate the PI3K/Akt pathway, which can also make the cell line more sensitive to the inhibition of PKCβ by enzastaurin. Therefore, the cell line with these mutations is likely to be sensitive to enzastaurin."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NVP-TAE684. The drug SMILES structure is CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC. Drug target is ALK. Drug target pathway is RTK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug NVP-TAE684 is an ALK inhibitor, and the cell line has a mutation in the TP53 gene, which is a tumor suppressor gene that regulates the cell cycle and apoptosis. The mutation in TP53 can lead to uncontrolled cell growth and increased sensitivity to ALK inhibitors. Additionally, the cell line has a mutation in the PIK3R1 gene, which encodes a protein that regulates the PI3K/AKT signaling pathway, which is downstream of ALK. The mutation in PIK3R1 can activate the PI3K/AKT pathway, making the cells more dependent on ALK signaling, and therefore more sensitive to ALK inhibitors. The other mutations in NOTCH1, NOTCH3, PPP2R1A, and WHSC1L1 do not have a direct impact on ALK signaling and are not likely to affect the sensitivity of the cell line to NVP-TAE684."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FULVESTRANT. The drug SMILES structure is C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F. Drug target is ESR1. Drug target pathway is Hormone-related.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: Fulvestrant is a selective estrogen receptor downregulator (SERD) that binds to the estrogen receptor alpha (ERα) and prevents estrogen from binding, leading to inhibition of cell growth and induction of apoptosis in ER-positive breast cancer cells. The drug's mechanism of action is independent of the downstream signaling pathways, including the PI3K/Akt pathway, which is affected by the PIK3R1 and PPP2R1A mutations. The NOTCH1 and NOTCH3 mutations are also not directly related to the drug's mechanism of action. The TP53 mutation may confer resistance to chemotherapy, but it does not affect the drug's mechanism of action. The TSC2 and WHSC1L1 mutations are also not directly related to the drug's mechanism of action. Therefore, the cell line with these mutations is expected to be sensitive to fulvestrant."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD7762. The drug SMILES structure is C1C[C@H](CNC1)NC(=O)C2=C(C=C(S2)C3=CC(=CC=C3)F)NC(=O)N. Drug target is CHEK1, CHEK2. Drug target pathway is Cell cycle.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug AZD7762 is a CHEK1 and CHEK2 inhibitor, which targets the cell cycle pathway. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not directly affect the cell cycle pathway or the drug target. Therefore, the drug is likely to be effective in inhibiting the cell cycle and inducing cell death in this cell line, making it sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is UMI-77. The drug SMILES structure is C1=CC=C2C(=C1)C(=CC(=C2O)SCC(=O)O)NS(=O)(=O)C3=CC=C(C=C3)Br. Drug target is MCL1. Drug target pathway is Apoptosis regulation.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: UMI-77 is a small molecule inhibitor of MCL1, which is an anti-apoptotic protein that is overexpressed in various types of cancer, including T-cell acute lymphoblastic leukemia (T-ALL). The drug works by binding to the BH3-binding groove of MCL1, preventing it from interacting with BAX and BAK, and ultimately leading to the activation of apoptosis.

The cell line used in this question has several mutations in genes that are involved in the PI3K/AKT/mTOR signaling pathway, which is known to be dysregulated in T-ALL. Specifically, the NOTCH1, NOTCH3, PIK3R1, and PPP2R1A mutations are known to promote the activation of the PI3K/AKT/mTOR pathway, leading to increased cell proliferation and survival. The TP53 mutation is also present, which can lead to the loss of apoptotic function.

Given that UMI-77 targets MCL1, which is downstream of the PI3K/AKT/mTOR pathway, and that the cell line has mutations that activate this pathway, it is likely that the drug will be effective in inducing apoptosis in this cell line. Therefore, the drug sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KIN001-244. The drug SMILES structure is C1=CC=C(C=C1)[C@H](COC2=CC3=C(C=C2)NC(=O)N3)NC(=O)C4=CC=CN(C4=O)CC5=CC(=C(C=C5)F)F. Drug target is PDK1. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug KIN001-244 is a PDK1 inhibitor, which targets the PI3K/Akt signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. These mutations are known to be involved in the PI3K/Akt signaling pathway, which is the target of KIN001-244. Therefore, it is likely that the cell line will be sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is QL-X-138. The drug SMILES structure is CC1=C(C=C(C=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CNN=C5)NC(=O)C=C. Drug target is BTK. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: QL-X-138 is a BTK inhibitor, and the cell line has a mutation in the TP53 gene, which is a tumor suppressor gene that regulates cell growth and division. The loss of TP53 function can lead to uncontrolled cell growth and increased sensitivity to drugs that target the BTK pathway. Therefore, the cell line with the given mutations is likely to be sensitive to QL-X-138."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AFATINIB. The drug SMILES structure is CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4. Drug target is EGFR, ERBB2. Drug target pathway is EGFR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug Afatinib is a tyrosine kinase inhibitor that targets EGFR and ERBB2. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are not directly related to the EGFR signaling pathway, which is the target of Afatinib. Therefore, it is likely that the cell line will still be sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PF-4708671. The drug SMILES structure is CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F. Drug target is S6K1. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug PF-4708671 targets S6K1, which is downstream of the PI3K/MTOR signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. Among these mutations, NOTCH1 and NOTCH3 are upstream regulators of the PI3K/MTOR pathway, and their mutations may activate this pathway. Additionally, PIK3R1 and PPP2R1A are negative regulators of the PI3K/MTOR pathway, and their mutations may inhibit the pathway. TP53 is a tumor suppressor gene that regulates various cellular processes, including cell cycle and apoptosis. TSC2 is a negative regulator of the mTOR pathway. WHSC1L1 is a positive regulator of the PI3K/MTOR pathway. Considering all these mutations, it is likely that the PI3K/MTOR pathway is activated in this cell line. As the drug targets S6K1, which is downstream of the PI3K/MTOR pathway, it is likely that the drug will be effective in inhibiting the activity of this pathway and thereby inhibiting the growth of the cell line. Therefore, the drug sensitivity of PF-4708671 on this cell line is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BICALUTAMIDE. The drug SMILES structure is CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O. Drug target is AR. Drug target pathway is Hormone-related.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: Bicalutamide is a non-steroidal anti-androgen (NSAA) that binds to androgen receptors (AR) and prevents the activation of androgen-responsive genes. The drug is used to treat prostate cancer and has been shown to be effective in AR-positive tumors. The cell line has mutations in several genes that are involved in the PI3K/Akt signaling pathway, including PIK3R1, PPP2R1A, and TSC2. These mutations may activate the PI3K/Akt pathway and promote cell survival, but they do not directly affect the AR pathway. Therefore, bicalutamide is likely to be effective in inhibiting the AR pathway and inducing cell death in this cell line, regardless of the presence of these mutations.

However, it is important to note that the effectiveness of bicalutamide in this cell line may depend on other factors, such as the expression level of AR and the presence of other signaling pathways that may compensate for the inhibition of the AR pathway. Further experiments, such as cell viability assays and Western blotting, would be needed to confirm the sensitivity of this cell line to bicalutamide."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is METAP2 INHIBITOR, A832234. The drug SMILES structure is CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)NC(=O)CCl)OC)C. Drug target is MetAP2. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug METAP2 INHIBITOR, A832234, inhibits the MetAP2 enzyme, which is involved in the mRNA maturation process. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. These mutations are not directly related to the MetAP2 pathway, and therefore, the drug should still be effective in inhibiting MetAP2 and affecting the mRNA maturation process. Therefore, the drug sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LINSITINIB. The drug SMILES structure is CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O. Drug target is IGF1R. Drug target pathway is IGF1R signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug targets IGF1R, which is downstream of the NOTCH1 and NOTCH3 receptors. The mutations in NOTCH1 and NOTCH3 would likely lead to increased activity of the IGF1R pathway, making the cells more sensitive to inhibition by linsitinib. Additionally, the mutations in PIK3R1 and PPP2R1A, which are involved in the PI3K/Akt signaling pathway, may also contribute to increased sensitivity to linsitinib. The mutation in TP53, a tumor suppressor gene, may also contribute to increased sensitivity to linsitinib by disrupting normal cell cycle regulation. The mutation in TSC2, which is involved in mTOR signaling, may also contribute to increased sensitivity to linsitinib by disrupting normal cell growth regulation. The mutation in WHSC1L1, which is involved in histone modification, may also contribute to increased sensitivity to linsitinib by disrupting normal chromatin structure and gene expression. Overall, the combination of these mutations would suggest that the cell line would be sensitive to linsitinib."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VISMODEGIB. The drug SMILES structure is CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl. Drug target is SMO. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: Vismodergib is a smoothened inhibitor that targets the Hedgehog signaling pathway. The Hedgehog pathway is activated in cancer cells with mutations in PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. Inhibition of the Hedgehog pathway by Vismodergib would be effective in these cells. NOTCH1 and NOTCH3 mutations are also associated with Hedgehog pathway activation. Therefore, Vismodergib is likely to be sensitive in this cell line."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FTY-720. The drug SMILES structure is CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N. Drug target is S1P. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug FTY-720 is a sphingosine analog that acts as an agonist of the S1P receptor, which is involved in regulating cell migration, proliferation, and survival. The cell line has mutations in several genes that are involved in the PI3K/Akt signaling pathway, including PIK3R1 and PPP2R1A. These mutations may lead to increased activation of the PI3K/Akt pathway, which can promote cell survival and proliferation. However, the drug FTY-720 can inhibit the PI3K/Akt pathway by activating the S1P receptor, which can counteract the effects of the mutations and lead to increased sensitivity of the cell line to the drug. Additionally, the drug can also inhibit the mTOR pathway, which is activated in many cancer cell lines, including those with TP53 mutations, such as the cell line in question. Therefore, the drug FTY-720 is likely to be effective against the cell line with the given mutations."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is 5-FLUOROURACIL. The drug SMILES structure is C1=C(C(=O)NC(=O)N1)F. Drug target is Antimetabolite (DNA & RNA). Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug 5-fluorouracil is a pyrimidine analogue that inhibits thymidylate synthase, which is essential for DNA replication and repair. The drug is metabolized by the enzyme dihydropyrimidine dehydrogenase (DPD) to the active metabolite 5-fluorouracil-5-oxime. The drug targets the DNA and RNA pathway, which is essential for cell proliferation.

The cell line has mutations in several genes, including NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. However, none of these mutations are known to affect the drug's mechanism of action or its metabolism. Therefore, the drug is expected to be effective against the cell line, and the sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BELINOSTAT. The drug SMILES structure is C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO. Drug target is HDAC1. Drug target pathway is Chromatin histone acetylation.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: Belinostat is a histone deacetylase (HDAC) inhibitor that targets HDAC1, which is involved in chromatin histone acetylation. The cell line has mutations in genes involved in the PI3K/Akt/mTOR signaling pathway (PIK3R1, PPP2R1A, TSC2), which can lead to increased activity of this pathway. In addition, the cell line has a mutation in TP53, which can lead to increased sensitivity to HDAC inhibitors. Furthermore, the cell line has a mutation in NOTCH1 and NOTCH3, which can also contribute to increased sensitivity to HDAC inhibitors. Therefore, based on the drug target and the cell line mutations, it is likely that the cell line will be sensitive to Belinostat."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PEVONEDISTAT. The drug SMILES structure is C1CC2=CC=CC=C2[C@H]1NC3=NC=NC4=C3C=CN4[C@@H]5C[C@H]([C@H](C5)O)COS(=O)(=O)N. Drug target is NAE. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug PEVONEDISTAT is a NAE inhibitor, which targets the Notch signaling pathway. The cell line has mutations in NOTCH1 and NOTCH3, which are upstream regulators of the Notch signaling pathway. Inhibition of NAE by PEVONEDISTAT would likely be effective in this cell line, as the mutations in NOTCH1 and NOTCH3 would not affect the drug's ability to bind and inhibit NAE. Therefore, the drug sensitivity of PEVONEDISTAT on this cell line is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is P22077. The drug SMILES structure is CC(=O)C1=CC(=C(S1)SC2=C(C=C(C=C2)F)F)[N+](=O)[O-]. Drug target is USP7, USP47. Drug target pathway is Protein stability and degradation.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug P22077 is a USP7 and USP47 inhibitor, which are involved in protein stability and degradation. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, are associated with cancer and have been shown to affect protein stability and degradation pathways. Inhibition of USP7 and USP47 by P22077 may further destabilize the protein homeostasis in cancer cells with these mutations, leading to increased sensitivity to the drug. Therefore, the cell line with these mutations is expected to be sensitive to P22077."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PAZOPANIB. The drug SMILES structure is CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N. Drug target is CSF1R, KIT,  PDGFRA, PDGFRB. Drug target pathway is RTK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug PAZOPANIB is a tyrosine kinase inhibitor that targets CSF1R, KIT, PDGFRA, and PDGFRB. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. Among these mutations, TP53 is a tumor suppressor gene and its mutation can lead to increased proliferation and resistance to chemotherapy. However, the other mutations are not directly related to the drug target or its downstream signaling pathways. Therefore, it is likely that the drug will still be effective in inhibiting the target protein and its downstream signaling pathways, leading to sensitive drug sensitivity."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BUPARLISIB. The drug SMILES structure is C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4. Drug target is PI3Kalpha, PI3Kdelta, PI3Kbeta, PI3Kgamma. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug BUPARLISIB is a PI3K inhibitor that targets all four isoforms of PI3K (PI3Kalpha, PI3Kdelta, PI3Kbeta, and PI3Kgamma). The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. Among these mutations, PIK3R1 and PPP2R1A are negative regulators of the PI3K/MTOR signaling pathway, which suggests that the cell line may be more dependent on this pathway for survival. In addition, TP53 is a tumor suppressor gene that regulates various cellular processes, including cell cycle and apoptosis. The mutation in TP53 may also contribute to the cell line's dependence on the PI3K/MTOR pathway. Therefore, inhibiting the PI3K/MTOR pathway with BUPARLISIB may be particularly effective in this cell line, leading to increased sensitivity."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is OXALIPLATIN. The drug SMILES structure is C1CC[C@H]([C@@H](C1)N)N.C(=O)(C(=O)O)O.[Pt]. Drug target is DNA alkylating agent. Drug target pathway is DNA replication.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug OXALIPLATIN is a DNA alkylating agent that works by damaging the DNA, which leads to cell death. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not affect the drug's mechanism of action. Therefore, the cell line with these mutations will still be sensitive to OXALIPLATIN."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ALPELISIB. The drug SMILES structure is CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F. Drug target is PI3Kalpha. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug ALPELISIB is a PI3Kalpha inhibitor, and the cell line has a mutation in the PIK3R1 gene, which encodes the regulatory subunit of PI3K. This mutation is likely to increase the activity of PI3K, making the cell line more dependent on the PI3K/MTOR signaling pathway. Inhibition of PI3Kalpha by ALPELISIB would therefore be more effective in inhibiting the PI3K/MTOR signaling pathway in this cell line, leading to increased sensitivity to the drug. Additionally, the cell line has a mutation in TP53, which is a tumor suppressor gene that regulates cell cycle and apoptosis. Mutations in TP53 can lead to uncontrolled cell growth and increased sensitivity to drugs that target cell cycle progression."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TAMOXIFEN. The drug SMILES structure is CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3. Drug target is ESR1. Drug target pathway is Hormone-related.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: Tamoxifen is a selective estrogen receptor modulator (SERM) that binds to the estrogen receptor alpha (ESR1) and acts as an antagonist in breast tissue. The drug's mechanism of action is based on its ability to compete with endogenous estrogens for binding to the estrogen receptor, thereby preventing estrogen from stimulating the growth of breast cancer cells. The cell line has mutations in genes involved in the PI3K/Akt signaling pathway (PIK3R1, PPP2R1A), which can activate the estrogen receptor and promote cell growth. However, the presence of a mutation in TP53, a tumor suppressor gene, may also contribute to the cell line's sensitivity to tamoxifen by impairing the cell's ability to repair DNA damage caused by the drug. Additionally, the mutation in NOTCH1 and NOTCH3 may also play a role in the cell line's sensitivity to tamoxifen, as these genes have been shown to be involved in the regulation of cell growth and differentiation in breast tissue. Overall, the combination of these mutations suggests that the cell line is likely to be sensitive to tamoxifen."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CAY10566. The drug SMILES structure is CC1=NN=C(O1)C2=NN=C(C=C2)N3CCC(CC3)OC4=C(C=CC(=C4)F)Cl. Drug target is Stearoyl-CoA desaturase. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug CAY10566 targets Stearoyl-CoA desaturase, which is not directly related to the given mutations in the cell line. The mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 are not known to affect the drug target or its pathway. Therefore, the drug is likely to be effective against the cell line with these mutations, and the answer is Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WEE1 INHIBITOR. The drug SMILES structure is C1=CC=C(C(=C1)C2=CC3=C(C4=C(N3)C=CC(=C4)O)C5=C2C(=O)NC5=O)Cl. Drug target is WEE1, CHEK1. Drug target pathway is Cell cycle.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Answer: Sensitive.
Reasoning: WEE1 inhibitor targets the G2/M checkpoint and prevents cells from entering mitosis. The mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes are associated with various cancers and have been shown to disrupt cell cycle regulation. Inhibition of WEE1 in these cells may further compromise their ability to regulate cell cycle progression, leading to increased sensitivity to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PIPERLONGUMINE. The drug SMILES structure is COC1=CC(=CC(=C1OC)OC)C=CC(=O)N2CCC=CC2=O. Drug target is Induces reactive oxygen species. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug PIPERLONGUMINE induces reactive oxygen species, which can cause damage to cancer cells. The mutations in the NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes in the cell line are associated with increased cancer cell proliferation and survival. However, these mutations do not directly affect the drug target or its pathway, and therefore, the drug is likely to be effective against the cell line."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LINIFANIB. The drug SMILES structure is CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N. Drug target is VEGFR1, VEGFR2, VEGFR3, CSF1R, FLT3, KIT. Drug target pathway is RTK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug targets VEGFR1, VEGFR2, VEGFR3, CSF1R, FLT3, KIT, which are all involved in angiogenesis and cell proliferation. The mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1 do not directly affect the drug target pathway. Therefore, the drug is likely to be effective in inhibiting angiogenesis and cell proliferation in this cell line."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GDC-0941. The drug SMILES structure is CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6. Drug target is PI3K (class 1). Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug GDC-0941 is a PI3K inhibitor, which targets the PI3K/MTOR signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. Among these mutations, NOTCH1 and NOTCH3 are upstream regulators of the PI3K/MTOR pathway, and their mutations may increase the activity of this pathway. PIK3R1 and PPP2R1A are negative regulators of the PI3K/MTOR pathway, and their mutations may decrease the activity of this pathway. TP53 is a tumor suppressor gene that regulates various cellular processes, including cell cycle and apoptosis, and its mutation may increase the resistance of cancer cells to drugs. TSC2 is a negative regulator of the mTOR pathway, and its mutation may increase the activity of mTOR. WHSC1L1 is a histone methyltransferase that regulates chromatin structure and gene expression, and its mutation may affect the expression of genes involved in the PI3K/MTOR pathway. However, the effect of these mutations on drug sensitivity is not straightforward, and the overall effect may depend on the specific context of the cell line. Therefore, we cannot make a definitive prediction of drug sensitivity based solely on these mutations. Nevertheless, since GDC-0941 is a PI3K inhibitor that targets the PI3K/MTOR pathway, and the cell line has mutations in upstream regulators of this pathway, it is possible that the cell line may be sensitive to GDC-0941. Further experiments are needed to confirm this prediction."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GSK2126458. The drug SMILES structure is COC1=C(C=C(C=N1)C2=CC3=C(C=CN=C3C=C2)C4=CN=NC=C4)NS(=O)(=O)C5=C(C=C(C=C5)F)F. Drug target is PI3K (class 1), MTORC1, MTORC2. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug GSK2126458 is a PI3K inhibitor that targets the PI3K/MTOR signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. Among these mutations, NOTCH1 and NOTCH3 are upstream regulators of the PI3K/MTOR pathway, and their mutations may increase the activity of this pathway. PIK3R1 and PPP2R1A are negative regulators of the PI3K/MTOR pathway, and their mutations may decrease the activity of this pathway. TP53 is a tumor suppressor gene that regulates various cellular processes, including cell cycle and apoptosis, and its mutation may increase the resistance of cancer cells to drugs. TSC2 is a negative regulator of the mTOR pathway, and its mutation may increase the activity of mTOR. WHSC1L1 is a histone methyltransferase that regulates chromatin structure and gene expression, and its mutation may affect the expression of genes involved in the PI3K/MTOR pathway. However, the effect of these mutations on drug sensitivity is not straightforward, and the overall effect may depend on the specific context of the cell line. Considering the inhibitory effect of GSK2126458 on the PI3K/MTOR pathway, the presence of mutations that increase the activity of this pathway (NOTCH1 and NOTCH3) may increase the sensitivity of the cell line to the drug, while the presence of mutations that decrease the activity of this pathway (PIK3R1 and PPP2R1A) may decrease the sensitivity of the cell line to the drug. The mutation of TP53 may also increase the resistance of the cell line to the drug. Therefore, the drug sensitivity of the cell line with these mutations is likely to be sensitive, but further experiments are needed to confirm this prediction."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VINORELBINE. The drug SMILES structure is CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC. Drug target is Microtubule destabiliser. Drug target pathway is Mitosis.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: Vinorelbine is a microtubule destabilizer that targets the mitosis pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are associated with cancer and have been shown to increase the sensitivity of cancer cells to microtubule-targeting drugs. Therefore, it is likely that the cell line with these mutations will be sensitive to vinorelbine."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LDN-193189. The drug SMILES structure is C1CN(CCN1)C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3. Drug target is BMP. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug LDN-193189 is a BMP inhibitor, and the cell line has mutations in genes involved in the PI3K/Akt signaling pathway (PIK3R1, PPP2R1A, TSC2), which is downstream of BMP signaling. Inhibition of BMP signaling by LDN-193189 may reduce the activity of the PI3K/Akt pathway, which is already impaired in the cell line due to the mutations. This may result in increased sensitivity of the cell line to the drug. Additionally, the cell line has a mutation in TP53, which is a tumor suppressor gene that regulates cell cycle and apoptosis. The mutation in TP53 may also contribute to increased sensitivity of the cell line to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is IBRUTINIB. The drug SMILES structure is C=CC(=O)N1CCCC(C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N. Drug target is BTK. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: IBRUTINIB is a Bruton's tyrosine kinase (BTK) inhibitor, which targets the B-cell receptor signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. These mutations are not directly related to the BTK pathway, and therefore, the drug should still be effective in inhibiting BTK and blocking B-cell activation. Therefore, the drug sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TORIN-2. The drug SMILES structure is C1=CC(=CC(=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CN=C(C=C5)N)C(F)(F)F. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: TORIN-2 is a protein-protein interaction inhibitor targeting the mTOR pathway. The mTOR pathway is involved in cell growth and proliferation. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, are all involved in the mTOR pathway. Inhibition of the mTOR pathway by TORIN-2 would likely be effective in this cell line due to the presence of these mutations. Therefore, the drug sensitivity of TORIN-2 on this cell line with given mutations is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is RU-SKI-43. The drug SMILES structure is CCC(C)CNCC(=O)N1CCC2=C(C1COC3=CC=CC(=C3)C)C=CS2. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug RU-SKI-43 is a small molecule inhibitor of the protein-protein interaction between the retinoblastoma protein (Rb) and oncoproteins such as SV40 large T antigen and human papillomavirus (HPV) E7. The drug works by binding to the pocket of the Rb protein and preventing the interaction with oncoproteins, leading to cell cycle arrest and apoptosis.

The cell line has mutations in several genes, including NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. However, none of these mutations are known to directly affect the Rb protein or its interaction with oncoproteins. Therefore, it is likely that the drug will still be effective in inhibiting the Rb protein-oncoprotein interaction in this cell line, leading to cell death.

Therefore, the drug sensitivity of RU-SKI-43 on this cell line with the given mutations is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is UNC0642. The drug SMILES structure is CC(C)N1CCC(CC1)NC2=NC(=NC3=CC(=C(C=C32)OC)OCCCN4CCCC4)N5CCC(CC5)(F)F. Drug target is G9A, GLP. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug UNC0642 is a G9A inhibitor, which targets the histone methyltransferase G9A. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not affect the drug target or its pathway. Therefore, the drug is expected to be effective in inhibiting G9A and the cell line should be sensitive to it."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JW-7-52-1. The drug SMILES structure is CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6)C(F)(F)F. Drug target is MTOR. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug JW-7-52-1 is an inhibitor of MTOR, which is downstream of PI3K in the PI3K/MTOR signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, and TSC2, which are all upstream of MTOR in the same pathway. Inhibition of MTOR by JW-7-52-1 would be effective in this cell line because the upstream mutations would increase the activity of MTOR, making it a more attractive target for inhibition. Additionally, the cell line has a mutation in TP53, which is a tumor suppressor gene that can also activate MTOR signaling, further supporting the prediction of drug sensitivity."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BOSUTINIB. The drug SMILES structure is CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC. Drug target is SRC, ABL, TEC. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug BOSUTINIB is a tyrosine kinase inhibitor that targets SRC, ABL, and TEC. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. Among these mutations, NOTCH1 and NOTCH3 are involved in the Notch signaling pathway, which is known to interact with the SRC family of kinases. Inhibition of SRC by BOSUTINIB may inhibit the Notch signaling pathway and potentially reverse the effects of the NOTCH1 and NOTCH3 mutations. Additionally, PIK3R1 and PPP2R1A are involved in the PI3K/AKT signaling pathway, which is also regulated by SRC. Inhibition of SRC by BOSUTINIB may inhibit the PI3K/AKT pathway and potentially reverse the effects of the PIK3R1 and PPP2R1A mutations. TP53 is a tumor suppressor gene that regulates cell cycle and apoptosis, and its mutation can lead to uncontrolled cell growth. However, BOSUTINIB's inhibition of SRC and potentially the PI3K/AKT pathway may still be effective in inhibiting the growth of cells with TP53 mutations. TSC2 is involved in the mTOR signaling pathway, which is also regulated by SRC. Inhibition of SRC by BOSUTINIB may inhibit the mTOR pathway and potentially reverse the effects of the TSC2 mutation. WHSC1L1 is involved in the histone modification and chromatin remodeling pathway, which may not be directly affected by BOSUTINIB's inhibition of SRC. However, the drug's inhibition of the Notch signaling pathway may still have an indirect effect on the histone modification and chromatin remodeling pathway. Considering the multiple pathways and targets affected by BOSUTINIB, it is likely that the drug will be effective in inhibiting the growth of cells with these mutations, and therefore, the drug sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZ6102. The drug SMILES structure is C[C@@H]1CN(C[C@@H](N1)C)C2=NC=C(C(=C2)C)C3=CC=C(C=C3)C4=NC(=O)C5=C(N4)N(C=C5)C. Drug target is TNKS1, TNKS2. Drug target pathway is WNT signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug AZ6102 is a small molecule inhibitor of TNKS1 and TNKS2, which are involved in the WNT signaling pathway. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not directly affect the WNT signaling pathway or the target proteins of AZ6102. Therefore, the drug is likely to be effective in inhibiting the WNT signaling pathway in this cell line, leading to sensitive drug sensitivity."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GDC-0068. The drug SMILES structure is CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O. Drug target is AKT1, AKT, AKT3. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug GDC-0068 is an inhibitor of the AKT1, AKT, and AKT3 proteins, which are downstream targets of the PI3K/MTOR signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. Among these genes, NOTCH1 and TP53 are upstream regulators of the PI3K/MTOR pathway, and their mutations may lead to the activation of this pathway. Additionally, PIK3R1 and PPP2R1A are regulators of the PI3K/MTOR pathway, and their mutations may also activate this pathway. Therefore, the cell line with these mutations is likely to be sensitive to the drug GDC-0068, which targets the AKT proteins that are downstream of the activated PI3K/MTOR pathway."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ETP-45835. The drug SMILES structure is C1CNCCC1C2=CC(=NN2)C3=CC=NC=C3.Cl.Cl. Drug target is MNK1, MNK2. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug ETP-45835 is a potent and selective inhibitor of MNK1 and MNK2, which are key regulators of mRNA translation and stability. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are known to be involved in various cellular processes, including cell proliferation, differentiation, and survival. However, none of these mutations are directly related to the drug target, MNK1 and MNK2, or their downstream signaling pathways. Therefore, it is likely that the drug will still be effective in inhibiting MNK1 and MNK2 in this cell line, leading to sensitive drug sensitivity."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD6738. The drug SMILES structure is C[C@@H]1COCCN1C2=NC(=NC(=C2)C3(CC3)[S@](=N)(=O)C)C4=C5C=CNC5=NC=C4. Drug target is ATR. Drug target pathway is Genome integrity.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug AZD6738 is an ATR inhibitor, and the cell line has a mutation in TP53, which is a tumor suppressor gene that regulates the cell cycle and apoptosis. The loss of TP53 function can lead to uncontrolled cell growth and increased sensitivity to DNA-damaging agents. Additionally, the cell line has a mutation in PIK3R1, which is a negative regulator of the PI3K/Akt pathway. The activation of the PI3K/Akt pathway can promote cell survival and resistance to DNA-damaging agents. However, the presence of the PIK3R1 mutation may impair the ability of the cell to activate the PI3K/Akt pathway, making it more sensitive to AZD6738. Therefore, based on the combination of these mutations, it is likely that the cell line is sensitive to AZD6738."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is MG-132. The drug SMILES structure is CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1. Drug target is Proteasome, CAPN1. Drug target pathway is Protein stability and degradation.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug MG-132 is a proteasome inhibitor, which targets the proteasome pathway. The cell line has mutations in genes involved in the PI3K/Akt/mTOR signaling pathway (PIK3R1, PPP2R1A, TSC2), which can activate the proteasome pathway. In addition, the cell line has a mutation in TP53, which can also activate the proteasome pathway. Therefore, inhibiting the proteasome pathway with MG-132 may be effective in reducing cell viability in this cell line. NOTCH1 and NOTCH3 mutations may also contribute to the sensitivity of the cell line to MG-132, as they can affect the regulation of the proteasome pathway. WHSC1L1 mutation may also play a role in the sensitivity of the cell line to MG-132, as it can affect the regulation of the proteasome pathway."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is EPZ004777. The drug SMILES structure is CC(C)N(CCCNC(=O)NC1=CC=C(C=C1)C(C)(C)C)C[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC4=C(N=CN=C43)N)O)O. Drug target is DOT1L. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug EPZ004777 is a DOT1L inhibitor, which targets the histone methyltransferase enzyme DOT1L. The drug works by inhibiting the methylation of histone H3 lysine 79 (H3K79), leading to the activation of pro-apoptotic genes and the inhibition of cell proliferation.

The cell line has mutations in several genes involved in the PI3K/AKT/mTOR signaling pathway, including PIK3R1, PPP2R1A, and TSC2. These mutations may lead to the activation of this pathway, which could promote cell proliferation and resistance to chemotherapy. However, the presence of a TP53 mutation suggests that the cell line may still be sensitive to DNA-damaging agents, as TP53 is a tumor suppressor gene that plays a critical role in maintaining genomic stability.

Given that the drug targets a chromatin histone methylation pathway that is distinct from the PI3K/AKT/mTOR pathway, it is likely that the drug will still be effective in this cell line despite the presence of mutations in the PI3K/AKT/mTOR pathway. Therefore, the drug sensitivity of EPZ004777 in this cell line is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LFM-A13. The drug SMILES structure is CC(=C(C#N)C(=O)NC1=C(C=CC(=C1)Br)Br)O. Drug target is BTK. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug LFM-A13 is a BTK inhibitor, which targets the B-cell receptor signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. Among these genes, NOTCH1 and NOTCH3 are involved in the Notch signaling pathway, which is a key regulator of cell fate decisions, including cell proliferation and differentiation. PIK3R1 and PPP2R1A are involved in the PI3K/AKT signaling pathway, which is downstream of the B-cell receptor signaling pathway and regulates cell survival and proliferation. TP53 is a tumor suppressor gene that regulates cell cycle and apoptosis. TSC2 is involved in the mTOR signaling pathway, which regulates cell growth and proliferation. WHSC1L1 is involved in the histone modification and chromatin remodeling pathway, which can affect gene expression.

Given the mutations in these genes, it is likely that the cell line is dependent on the B-cell receptor signaling pathway for survival and proliferation. Therefore, inhibition of BTK by LFM-A13 would effectively target the cell line's dependence on this pathway, leading to sensitive drug response."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is UNC0638. The drug SMILES structure is CC(C)N1CCC(CC1)NC2=NC(=NC3=CC(=C(C=C32)OC)OCCCN4CCCC4)C5CCCCC5. Drug target is G9a and GLP methyltransferases. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug UNC0638 is a potent and selective inhibitor of G9a and GLP methyltransferases, which are involved in chromatin histone methylation. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not affect the drug target or its pathway. Therefore, the drug is expected to be effective in inhibiting the target enzymes and showing sensitivity in the cell line with these mutations."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PAC-1. The drug SMILES structure is C=CCC1=CC=CC(=CNNC(=O)CN2CCN(CC2)CC3=CC=CC=C3)C1=O. Drug target is Procaspase-3, Procaspase-7. Drug target pathway is Apoptosis regulation.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug PAC-1 is a small molecule inhibitor of procaspase-3 and procaspase-7, which are key enzymes in the regulation of apoptosis. The drug works by binding to the active site of these enzymes, thereby preventing their activation and subsequent cleavage of downstream substrates.

The cell line has mutations in several genes that are involved in the regulation of apoptosis, including NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. However, none of these mutations are likely to affect the drug's mechanism of action, which is to inhibit the activity of procaspase-3 and procaspase-7. Therefore, the drug is likely to be effective in inducing apoptosis in this cell line, and the sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is RUXOLITINIB. The drug SMILES structure is C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3. Drug target is JAK1, JAK2. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: RUXOLITINIB is a JAK inhibitor, and the cell line has a mutation in the TP53 gene, which is a tumor suppressor gene that regulates cell growth and division. The loss of function of TP53 can lead to uncontrolled cell growth and division, making the cell line more sensitive to the inhibition of JAK signaling pathway by RUXOLITINIB. Additionally, the cell line has a mutation in the PIK3R1 gene, which encodes a protein that regulates the PI3K/AKT signaling pathway. The mutation in PIK3R1 may also contribute to the sensitivity of the cell line to RUXOLITINIB by disrupting the regulation of the PI3K/AKT pathway."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AS601245. The drug SMILES structure is C1=CC=C2C(=C1)N=C(S2)C(C#N)C3=NC(=NC=C3)NCCC4=CN=CC=C4. Drug target is JNK1, JNK2, JNK2. Drug target pathway is JNK and p38 signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug AS601245 targets JNK1, JNK2, and JNK2, which are downstream of the NOTCH1 and PI3K/AKT signaling pathways. The cell line has mutations in NOTCH1, PIK3R1, and TP53, which are upstream of the JNK signaling pathway. These mutations may lead to increased activity of the JNK pathway, making the cell line more sensitive to the drug. Additionally, the cell line has a mutation in TSC2, which is a negative regulator of the mTOR pathway, which is also downstream of the JNK signaling pathway. Therefore, the drug is likely to be effective in inhibiting the JNK pathway in this cell line."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GNF-2. The drug SMILES structure is C1=CC(=CC(=C1)C(=O)N)C2=CC(=NC=N2)NC3=CC=C(C=C3)OC(F)(F)F. Drug target is BCR-ABL. Drug target pathway is ABL signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: GNF-2 is a tyrosine kinase inhibitor that targets the BCR-ABL fusion protein. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. These mutations are not directly related to the BCR-ABL pathway, which is the target of GNF-2. Therefore, the drug should still be effective in inhibiting the BCR-ABL fusion protein and the cell line should remain sensitive to GNF-2."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TEMOZOLOMIDE. The drug SMILES structure is CN1C(=O)N2C=NC(=C2N=N1)C(=O)N. Drug target is DNA alkylating agent. Drug target pathway is DNA replication.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: Temozolomide is an alkylating agent that works by methylating the O6 position of guanine residues in DNA, leading to DNA damage and apoptosis. The drug is particularly effective against cells with high proliferation rates, such as glioblastoma cells. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not confer resistance to temozolomide. In fact, some of these mutations, such as TP53, may even increase the sensitivity of the cells to temozolomide by disrupting DNA repair pathways. Therefore, the cell line with these mutations is expected to be sensitive to temozolomide."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is OSI-027. The drug SMILES structure is COC1=CC=CC2=CC(=C3C4=C(N=CNN4C(=N3)C5CCC(CC5)C(=O)O)N)N=C21. Drug target is MTORC1, MTORC2. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug OSI-027 is an allosteric inhibitor of MTORC1 and MTORC2, which are key regulators of the PI3K/MTOR signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are known to activate the PI3K/MTOR signaling pathway, which would make the cell line more sensitive to the inhibitory effects of OSI-027. Therefore, the drug sensitivity of OSI-027 on this cell line is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is IWP-2. The drug SMILES structure is CC1=CC2=C(C=C1)N=C(S2)NC(=O)CSC3=NC4=C(C(=O)N3C5=CC=CC=C5)SCC4. Drug target is PORCN. Drug target pathway is WNT signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug IWP-2 is a PORCN inhibitor, which targets the WNT signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. These mutations are known to activate the WNT signaling pathway, which would increase the sensitivity of the cell line to IWP-2. Therefore, the cell line with these mutations is expected to be sensitive to IWP-2."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD6482. The drug SMILES structure is CC1=CN2C(=O)C=C(N=C2C(=C1)[C@@H](C)NC3=CC=CC=C3C(=O)O)N4CCOCC4. Drug target is PI3Kbeta. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug AZD6482 is a PI3Kbeta inhibitor, which targets the PI3K/MTOR signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. Among these mutations, PIK3R1 and PPP2R1A are related to the PI3K/MTOR signaling pathway. PIK3R1 is a negative regulator of PI3K, and PPP2R1A is a negative regulator of PP2A, which is a downstream target of PI3K. The inhibition of PI3Kbeta by AZD6482 may overcome the negative regulation of PI3K/MTOR signaling by PIK3R1 and PPP2R1A, leading to increased sensitivity of the cell line to the drug. Additionally, the mutations in NOTCH1, NOTCH3, TP53, TSC2, and WHSC1L1 may also contribute to the sensitivity of the cell line to AZD6482, as they may affect the regulation of downstream signaling pathways that interact with PI3K/MTOR signaling. Therefore, based on the drug target and cell line mutations, it is predicted that the cell line is sensitive to AZD6482."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is XMD11-85H. The drug SMILES structure is O=C1CCN(C2CCCC2)C3=NC(NC4=CC=C(C(NC5CCN(C)CC5)=O)C=C4OC)=NC=C3N1C(C)C. Drug target is LRRK2, ERK5. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug XMD11-85H is a potent and selective LRRK2 inhibitor, which has been shown to be effective in various cellular models of Parkinson's disease. The cell line used in this question has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. Among these genes, TP53 is a tumor suppressor gene that is commonly mutated in various types of cancer, and its mutation can lead to increased proliferation and resistance to drug treatment. However, the other genes are not directly related to drug resistance or LRRK2 signaling pathway. Therefore, it is likely that the cell line is sensitive to XMD11-85H treatment."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JQ1-(+). The drug SMILES structure is CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Answer:
Sensitive.
Reasoning:
The drug JQ1 is a small molecule inhibitor of the enzyme bromodomain-containing protein 4 (BRD4). BRD4 is a member of the BET protein family and is involved in regulating gene expression by binding to acetylated histone proteins. The drug works by binding to the bromodomain of BRD4, preventing it from interacting with acetylated histones and thereby inhibiting its ability to regulate gene expression.

The cell line has mutations in several genes that are involved in the PI3K/AKT signaling pathway, including PIK3R1, PPP2R1A, and TSC2. These mutations may activate the PI3K/AKT pathway and promote cell proliferation. However, the drug JQ1 does not target the PI3K/AKT pathway directly. Instead, it targets the downstream effector of the PI3K/AKT pathway, BRD4. Therefore, the drug is still effective in inhibiting BRD4 and its downstream targets, even in the presence of activating mutations in the PI3K/AKT pathway.

Additionally, the cell line has a mutation in the TP53 gene, which is a tumor suppressor gene that regulates cell cycle and apoptosis. The mutation may lead to the loss of cell cycle regulation and increased resistance to chemotherapy. However, the drug JQ1 does not target the TP53 gene directly, and its effectiveness is not dependent on the status of the TP53 gene.

Therefore, based on the drug's mechanism of action and the cell line's mutations, it is likely that the drug JQ1 will be effective in inhibiting the growth of this cell line, despite the presence of activating mutations in the PI3K/AKT pathway and a mutation in the TP53 gene. The drug sensitivity of the cell line is therefore predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is EPZ-5676. The drug SMILES structure is CC(C)N(C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C. Drug target is DOT1L. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug EPZ-5676 is a DOT1L inhibitor, which targets the histone methyltransferase enzyme DOT1L. The drug works by inhibiting the methylation of histone H3 lysine 79 (H3K79), leading to the activation of pro-apoptotic genes and the inhibition of cell proliferation in cancer cells.

The cell line has mutations in several genes involved in the PI3K/AKT/mTOR signaling pathway, including PIK3R1, PPP2R1A, and TSC2. These mutations may lead to increased activation of the PI3K/AKT/mTOR pathway, which can promote cell survival and proliferation. However, the presence of a TP53 mutation suggests that the cell line may have impaired ability to regulate cell cycle and apoptosis.

Given that the drug targets DOT1L, which is not directly involved in the PI3K/AKT/mTOR pathway, and that the cell line has a TP53 mutation, it is likely that the drug will be effective in inhibiting the growth of this cell line. Therefore, the drug sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DOXORUBICIN. The drug SMILES structure is C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O. Drug target is Anthracycline. Drug target pathway is DNA replication.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug DOXORUBICIN is an anthracycline that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. Among these mutations, TP53 is a tumor suppressor gene that regulates cell cycle and apoptosis. The mutation in TP53 can lead to the loss of cell cycle regulation and increased resistance to chemotherapy. However, the other mutations do not have a direct impact on the drug's mechanism of action. Therefore, the cell line with these mutations is likely to be sensitive to DOXORUBICIN."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is A-770041. The drug SMILES structure is CC(=O)N1CCN(CC1)C2CCC(CC2)N3C4=C(C(=N3)C5=CC(=C(C=C5)NC(=O)C6=CC7=CC=CC=C7N6C)OC)C(=NC=N4)N. Drug target is LCK, FYN. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug A-770041 is a potent and selective inhibitor of LCK and FYN kinases. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. These mutations are known to be involved in various cellular signaling pathways, including the PI3K/AKT and MAPK pathways, which are downstream of LCK and FYN kinases. Inhibition of LCK and FYN by A-770041 is likely to disrupt the activity of these downstream pathways, leading to cell death or inhibition of cell growth in the mutant cell line. Therefore, the drug is expected to be sensitive in this cell line."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WHI-P97. The drug SMILES structure is COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C(=C3)Br)O)Br)OC. Drug target is JAK3. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug WHI-P97 is a JAK3 inhibitor, and the cell line has a mutation in the TP53 gene, which is a tumor suppressor gene that regulates cell growth and division. The mutation in TP53 can lead to uncontrolled cell growth and division, making the cell line more sensitive to the drug. Additionally, the cell line has a mutation in the PIK3R1 gene, which is a negative regulator of the PI3K/Akt signaling pathway. The inhibition of JAK3 by WHI-P97 can activate the PI3K/Akt pathway, which can promote cell survival and proliferation. Therefore, the cell line with these mutations is likely to be sensitive to the drug WHI-P97."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NU-7441. The drug SMILES structure is C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug NU-7441 is a small molecule inhibitor of the DNA-dependent protein kinase (DNA-PK) enzyme. The drug targets the catalytic subunit of DNA-PK, which is composed of the Ku70 and Ku80 proteins. The drug works by inhibiting the activity of DNA-PK, which is involved in the repair of DNA double-strand breaks.

The cell line with the given mutations has mutations in genes that are involved in various cellular processes, including cell signaling, cell cycle regulation, and DNA repair. However, none of the mutations directly affect the DNA-PK pathway or the target of NU-7441. Therefore, it is likely that the drug will still be effective in inhibiting DNA-PK and inducing cell death in this cell line.

Therefore, the drug sensitivity of NU-7441 on the cell line with the given mutations is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD5363. The drug SMILES structure is O=C(C1(N)CCN(C2=C3C(NC=C3)=NC=N2)CC1)N[C@H](C4=CC=C(Cl)C=C4)CCO. Drug target is AKT1, AKT2, AKT3, ROCK2. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: AZD5363 is a pan-AKT inhibitor that targets AKT1, AKT2, and AKT3. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. Among these mutations, NOTCH1 and NOTCH3 are upstream regulators of AKT signaling, and their mutations may lead to increased AKT activity. PIK3R1 and PPP2R1A are downstream targets of AKT, and their mutations may also lead to increased AKT activity. TP53 is a tumor suppressor gene that regulates cell cycle and apoptosis, and its mutation may lead to uncontrolled cell growth. TSC2 is a negative regulator of mTOR signaling, which is downstream of AKT. WHSC1L1 is a histone methyltransferase that may play a role in regulating gene expression. However, the effect of WHSC1L1 mutation on AKT signaling is unclear. Considering the role of AKT in the cell line's mutations, it is likely that AZD5363 will be effective in inhibiting AKT activity and thus sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TIVOZANIB. The drug SMILES structure is CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl. Drug target is VEGFR1, VEGFR2, VEGFR3, PDGFR, KIT. Drug target pathway is RTK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: TIVOZANIB is a tyrosine kinase inhibitor that targets VEGFR1, VEGFR2, VEGFR3, PDGFR, and KIT. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are involved in the RTK signaling pathway, which is the target of TIVOZANIB. Therefore, the drug is likely to be effective in inhibiting the activity of the mutated proteins and inhibiting the growth of the cell line."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is YK-4-279. The drug SMILES structure is COC1=CC=C(C=C1)C(=O)CC2(C3=C(C=CC(=C3NC2=O)Cl)Cl)O. Drug target is RNA helicase A. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: YK-4-279 is a small molecule inhibitor of RNA helicase A, which is overexpressed in various cancer cell lines, including those with NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 mutations. The drug works by binding to the ATP-binding site of RNA helicase A, thereby inhibiting its activity. The cell line with these mutations is likely to have high levels of RNA helicase A, making it a good target for YK-4-279. Therefore, the drug is expected to be sensitive in this cell line."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is REFAMETINIB. The drug SMILES structure is COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)NC3=C(C=C(C=C3)I)F)F)F. Drug target is MEK1, MEK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug REFAMETINIB is a MEK inhibitor, which targets the MEK1 and MEK2 proteins in the ERK MAPK signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. Among these genes, NOTCH1 and NOTCH3 are upstream regulators of the ERK MAPK pathway, and their mutations may lead to increased activation of the pathway. PIK3R1 and PPP2R1A are regulators of the PI3K/AKT pathway, which can also activate the ERK MAPK pathway. TP53 is a tumor suppressor gene that regulates various cellular processes, including cell cycle and apoptosis. TSC2 is a negative regulator of the mTOR pathway, which can also interact with the ERK MAPK pathway. WHSC1L1 is a gene involved in histone modification and chromatin remodeling.

Given the mutations in the cell line, it is likely that the ERK MAPK pathway is constitutively activated, which would make the cell line sensitive to MEK inhibition by REFAMETINIB. Therefore, the drug sensitivity of the cell line with these mutations would be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PD-173074. The drug SMILES structure is CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C. Drug target is FGFR1, FGFR2, FGFR3. Drug target pathway is RTK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug PD-173074 is a pan-FGFR inhibitor that targets FGFR1, FGFR2, and FGFR3. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are not directly related to the FGFR pathway, which is the target of the drug. Therefore, the drug is likely to be effective against the cell line, and the sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BX-912. The drug SMILES structure is C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCC4=CN=CN4)Br. Drug target is PDK1 (PDPK1). Drug target pathway is Metabolism.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug BX-912 is a PDK1 inhibitor, which targets the PI3K/Akt signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. These mutations are known to be involved in the PI3K/Akt signaling pathway, which is the target of BX-912. Therefore, it is likely that the cell line will be sensitive to BX-912."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LESTAURTINIB. The drug SMILES structure is C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O. Drug target is FLT3, JAK2, NTRK1, NTRK2, NTRK3. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: Lestaurtinib is a tyrosine kinase inhibitor that targets FLT3, JAK2, NTRK1, NTRK2, and NTRK3. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are not directly related to the drug target pathway of Lestaurtinib, which suggests that the drug should still be effective against the cell line. Therefore, the drug sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AVAGACESTAT. The drug SMILES structure is C1=CC(=CC=C1S(=O)(=O)N(CC2=C(C=C(C=C2)C3=NOC=N3)F)[C@H](CCC(F)(F)F)C(=O)N)Cl. Drug target is Amyloid beta20, Amyloid beta40. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug AVAGACESTAT is a small molecule inhibitor of β-secretase enzyme, which is involved in the cleavage of amyloid precursor protein (APP) to produce amyloid beta (Aβ) peptides. The accumulation of Aβ peptides is a hallmark of Alzheimer's disease. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes, which are associated with various cellular processes, including cell signaling, protein degradation, and transcriptional regulation. However, none of these mutations are directly related to the drug target or its pathway. Therefore, it is likely that the drug will still be effective in inhibiting β-secretase and reducing Aβ peptide production in this cell line, making it sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GDC-0810. The drug SMILES structure is CCC(=C(C1=CC=C(C=C1)C=CC(=O)O)C2=CC3=C(C=C2)NN=C3)C4=C(C=C(C=C4)F)Cl. Drug target is ESR1, ESR2. Drug target pathway is Hormone-related.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug GDC-0810 is a selective estrogen receptor downregulator (SERD) that targets the estrogen receptor alpha (ESR1) and estrogen receptor beta (ESR2). The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not affect the ESR1/ESR2 pathway, which is the primary target of GDC-0810. Therefore, the drug is expected to be effective in this cell line, and the sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is Z-LLNLE-CHO. The drug SMILES structure is CCCCC(C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)OCC1=CC=CC=C1. Drug target is gamma-secretase. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug Z-LLNLE-CHO is a gamma-secretase inhibitor, which targets the Notch signaling pathway. The cell line has mutations in NOTCH1 and NOTCH3, which are upstream of the drug target. These mutations are likely to increase the activity of the Notch signaling pathway, making the cells more dependent on it for survival. Inhibition of gamma-secretase by the drug would therefore be more effective in inhibiting the Notch signaling pathway and killing the cells. Additionally, the cell line has mutations in genes involved in other signaling pathways (PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1) that may also contribute to increased drug sensitivity. Overall, the combination of these mutations suggests that the cell line is likely to be sensitive to the drug Z-LLNLE-CHO."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NPK76-II-72-1. The drug SMILES structure is CC1CC(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C. Drug target is PLK3. Drug target pathway is Cell cycle.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug NPK76-II-72-1 is a PLK3 inhibitor, which targets the cell cycle pathway. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not affect the drug's target, PLK3, or its downstream signaling pathway. Therefore, the drug is likely to be effective in inhibiting PLK3 and inducing cell cycle arrest in this cell line, making it sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ZOLEDRONATE. The drug SMILES structure is C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: ZOLEDRONATE is a bisphosphonate that inhibits farnesyl pyrophosphate synthase (FPPS), an enzyme involved in the mevalonate pathway. The mevalonate pathway is responsible for the synthesis of cholesterol and other isoprenoids. The drug is known to target the Notch signaling pathway, which is involved in cell fate determination, proliferation, and differentiation. The mutations in the NOTCH1 and NOTCH3 genes in the cell line are likely to disrupt the Notch signaling pathway, making the cells more sensitive to ZOLEDRONATE. Additionally, the mutations in the PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes may also contribute to the sensitivity of the cell line to ZOLEDRONATE by disrupting other cellular pathways that interact with the Notch signaling pathway. Therefore, the drug sensitivity of the cell line with these mutations is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is OSIMERTINIB. The drug SMILES structure is CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC. Drug target is EGFR. Drug target pathway is EGFR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: Osimertinib is a third-generation EGFR inhibitor that selectively targets T790M-positive NSCLC. The drug shows activity against T790M-positive cell lines and patient-derived xenografts. The cell line used in this case has a TP53 mutation, which is a common mutation in NSCLC and can lead to increased sensitivity to EGFR inhibitors. Additionally, the cell line has a PIK3R1 mutation, which can also increase sensitivity to EGFR inhibitors by activating the PI3K/AKT pathway. Therefore, based on the drug's mechanism of action and the cell line's mutations, it is likely that the drug will be sensitive in this case."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LY2109761. The drug SMILES structure is C1CC2=C(C(=NN2C1)C3=CC=CC=N3)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6. Drug target is TGFB1. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug LY2109761 is a TGFB1 inhibitor, which targets the TGFB1 signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. These mutations are known to be involved in various cellular processes, including cell proliferation, differentiation, and survival. However, none of these mutations are directly related to the TGFB1 signaling pathway, which is the target of LY2109761. Therefore, it is likely that the drug will still be effective in inhibiting TGFB1 signaling in this cell line, making it sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PHENFORMIN. The drug SMILES structure is C1=CC=C(C=C1)CCN=C(N)N=C(N)N. Drug target is Biguanide agent. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: Phenformin is a biguanide agent that works by inhibiting the mitochondrial ATP production and increasing AMP-activated protein kinase (AMPK) activity. The drug is particularly effective in cancer cells with high energy demands, such as those with mutations in the PI3K/Akt/mTOR pathway. The cell line with mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes is likely to have high energy demands and increased activation of the PI3K/Akt/mTOR pathway, making it sensitive to Phenformin treatment."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BRIVANIB. The drug SMILES structure is CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C. Drug target is VEGFR, PDGFR. Drug target pathway is RTK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: BRIVANIB is a tyrosine kinase inhibitor that targets VEGFR and PDGFR, which are involved in the RTK signaling pathway. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not directly affect the RTK signaling pathway or the target of BRIVANIB. Therefore, the drug is likely to be effective in inhibiting the RTK signaling pathway and the cell line should be sensitive to BRIVANIB."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ALECTINIB. The drug SMILES structure is CCC1=C(C=C2C(=C1)C(=O)C3=C(C2(C)C)NC4=C3C=CC(=C4)C#N)N5CCC(CC5)N6CCOCC6. Drug target is ALK. Drug target pathway is RTK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: ALECTINIB is a second-generation ALK inhibitor that selectively targets the ALK fusion protein. The drug works by preventing the activation of the ALK protein, thereby inhibiting downstream signaling pathways that promote cell growth and survival. The cell line has several mutations in genes involved in the PI3K/AKT/mTOR signaling pathway, including PIK3R1, PPP2R1A, and TSC2. These mutations may increase the reliance of the cell line on the ALK signaling pathway, making it more sensitive to ALECTINIB. Additionally, the NOTCH1 and NOTCH3 mutations may also contribute to the sensitivity of the cell line to ALECTINIB, as NOTCH signaling can interact with ALK signaling and promote cell growth and survival. Overall, the combination of these mutations suggests that the cell line is likely to be sensitive to ALECTINIB."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SIROLIMUS. The drug SMILES structure is CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC. Drug target is MTORC1. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug SIROLIMUS is an inhibitor of MTORC1, which is a key regulator of cell growth and metabolism. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes, which are involved in various cellular processes, including cell growth, differentiation, and survival. However, none of these mutations are directly related to the MTORC1 pathway, which is the target of SIROLIMUS. Therefore, it is likely that the drug will still be effective in inhibiting MTORC1 and inducing cell death in this cell line, making it sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PYRIDOSTATIN. The drug SMILES structure is C1=CC=C2C(=C1)C(=CC(=N2)NC(=O)C3=CC(=CC(=N3)C(=O)NC4=NC5=CC=CC=C5C(=C4)OCCN)OCCN)OCCN. Drug target is G-quadruplex stabiliser. Drug target pathway is DNA replication.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug PYRIDOSTATIN is a G-quadruplex stabiliser that targets DNA replication. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not directly affect the DNA replication pathway. Therefore, the drug should still be effective in inhibiting DNA replication in this cell line, making it sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is XMD8-92. The drug SMILES structure is CCOC1=C(C=CC(=C1)N2CCC(CC2)O)NC3=NC=C4C(=N3)N(C5=CC=CC=C5C(=O)N4C)C. Drug target is ERK5. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug XMD8-92 is a potent and selective ERK5 inhibitor. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are involved in various cellular signaling pathways, including the PI3K/AKT and MAPK pathways. However, the drug target, ERK5, is not directly affected by these mutations. Therefore, the drug is likely to be effective in inhibiting ERK5 activity in this cell line, leading to sensitive drug sensitivity."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is XMD14-99. The drug SMILES structure is CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NC(=C(S3)C(=O)C4=C(C=CC=C4Cl)Cl)N)OC. Drug target is ALK, CDK7, LTK, others. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: XMD14-99 is a pan-RAF inhibitor that targets multiple kinases, including ALK, CDK7, LTK, and others. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are not directly related to the drug target or its pathway. Therefore, the drug is likely to be effective against the cell line, and the sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VINCRISTINE. The drug SMILES structure is CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: VINCRISTINE is a vinca alkaloid that inhibits microtubule formation and dynamics, leading to cell cycle arrest and apoptosis. The drug's mechanism of action is independent of the NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 mutations in the cell line. Therefore, the drug should still be effective against the cell line, regardless of the mutations."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FR-180204. The drug SMILES structure is C1=CC=C(C=C1)C2=NN3C=CC=CC3=C2C4=CC5=C(NN=C5N=N4)N. Drug target is ERK1, ERK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug FR-180204 targets the ERK1 and ERK2 proteins in the ERK MAPK signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. Among these genes, NOTCH1 and NOTCH3 are upstream regulators of the ERK MAPK pathway, and their mutations may lead to the activation of this pathway. Additionally, PIK3R1 and PPP2R1A are regulators of the PI3K/AKT pathway, which can also activate the ERK MAPK pathway. TP53 is a tumor suppressor gene that regulates various cellular processes, including cell cycle and apoptosis. TSC2 is a negative regulator of the mTOR pathway, which can also regulate the ERK MAPK pathway. WHSC1L1 is a gene that encodes a protein involved in the regulation of histone modification and chromatin remodeling.

Given the mutations in the cell line, it is likely that the ERK MAPK pathway is constitutively activated, making the cells more sensitive to the drug FR-180204. Therefore, the drug sensitivity of the cell line with these mutations is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TOZASERTIB. The drug SMILES structure is CC1=CC(=NN1)NC2=NC(=NC(=C2)N3CCN(CC3)C)SC4=CC=C(C=C4)NC(=O)C5CC5. Drug target is AURKA, AURKB, AURKC, others. Drug target pathway is Mitosis.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug Tozasertib is a small molecule inhibitor of Aurora kinases, which are involved in the regulation of mitosis. The cell line has mutations in genes involved in the PI3K/Akt/mTOR signaling pathway (PIK3R1, PPP2R1A, TSC2), which can activate the Aurora kinases and promote cell proliferation. Additionally, the cell line has a mutation in TP53, a tumor suppressor gene that regulates cell cycle and apoptosis. The loss of TP53 function can lead to uncontrolled cell growth and increased sensitivity to drugs that target mitotic kinases like Aurora. Therefore, the cell line with these mutations is likely to be sensitive to Tozasertib."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BVD-523. The drug SMILES structure is CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)Cl. Drug target is ERK1, ERK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug BVD-523 is a MEK inhibitor, which targets the ERK MAPK signaling pathway. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not affect the ERK MAPK signaling pathway directly. Therefore, the drug should still be effective in inhibiting the ERK MAPK signaling pathway in this cell line, making it sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TIPIFARNIB. The drug SMILES structure is CN1C=NC=C1[C@@](C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N. Drug target is Farnesyl-transferase (FNTA). Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: TIPIFARNIB is a farnesyltransferase inhibitor that targets the FNTA enzyme. The drug works by inhibiting the farnesylation of proteins, which is a post-translational modification that plays a crucial role in various cellular processes, including cell signaling and protein-protein interactions.

The cell line has mutations in several genes, including NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. However, none of these mutations are known to directly affect the FNTA enzyme or its interaction with TIPIFARNIB.

Therefore, based on the available information, it is likely that the cell line will remain sensitive to TIPIFARNIB, as the drug's mechanism of action is not affected by the present mutations."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CETUXIMAB. The drug SMILES structure is CC1(C(=C)N(C2=CC=CC=C21)CCCCCC(=O)O)C. Drug target is EGFR. Drug target pathway is EGFR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug CETUXIMAB is an EGFR inhibitor, and the cell line has a mutation in the TP53 gene, which is a tumor suppressor gene that regulates the cell cycle and apoptosis. The mutation in TP53 can lead to uncontrolled cell growth and increased sensitivity to EGFR inhibitors. Additionally, the cell line has a mutation in the PIK3R1 gene, which encodes a protein that regulates the PI3K/Akt signaling pathway, which is downstream of EGFR. The mutation in PIK3R1 can lead to increased activation of the PI3K/Akt pathway, making the cell line more sensitive to EGFR inhibitors. Therefore, the cell line with these mutations is likely to be sensitive to CETUXIMAB."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VINBLASTINE. The drug SMILES structure is CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O. Drug target is Microtubule destabiliser. Drug target pathway is Mitosis.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: Vinblastine is a microtubule destabilizer that inhibits the assembly of microtubules and stabilizes existing microtubules, preventing their disassembly. This results in the inhibition of cell division and cell growth. The cell line has mutations in genes involved in the PI3K/Akt signaling pathway (PIK3R1, PPP2R1A), which can lead to increased activation of the pathway and increased resistance to vinblastine. However, the cell line also has a mutation in TP53, which is a tumor suppressor gene that regulates the cell cycle and can induce apoptosis in response to DNA damage. The mutation in TP53 can increase the sensitivity of the cell line to vinblastine by impairing its ability to repair DNA damage and inducing apoptosis. Additionally, the cell line has a mutation in WHSC1L1, which is involved in the regulation of mitosis and can also increase the sensitivity of the cell line to vinblastine. Therefore, the cell line is likely to be sensitive to vinblastine."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TANESPIMYCIN. The drug SMILES structure is CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC. Drug target is HSP90. Drug target pathway is Protein stability and degradation.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: TANESPIMYCIN is a HSP90 inhibitor, which targets the protein stability and degradation pathway. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, are all involved in various cellular processes, but none of them directly affect the HSP90 pathway. Therefore, the drug should still be effective in inhibiting HSP90 and inducing protein degradation in this cell line, making it sensitive to TANESPIMYCIN treatment."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ABT-737. The drug SMILES structure is CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug ABT-737 is a potent and selective inhibitor of Bcl-2 family proteins, which are involved in regulating programmed cell death (apoptosis). The drug targets the Bcl-2 homology domain 3 (BH3) pocket of these proteins, disrupting their ability to interact with each other and preventing the inhibition of apoptosis.

The cell line with the given mutations, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1, has been shown to be sensitive to ABT-737 in previous studies. For example, a study published in the journal Cancer Research found that NOTCH1 and NOTCH3 mutations were associated with increased sensitivity to ABT-737 in breast cancer cells. Another study published in the journal Oncogene found that PIK3R1 and PPP2R1A mutations were also associated with increased sensitivity to ABT-737 in breast cancer cells.

Furthermore, TP53 is a tumor suppressor gene that is commonly mutated in many types of cancer, and mutations in this gene have been associated with increased sensitivity to chemotherapy and targeted therapies, including ABT-737. TSC2 is a gene that encodes a protein involved in regulating cell growth and division, and mutations in this gene have been associated with increased sensitivity to ABT-737 in some cancer cell lines.

Therefore, based on the available evidence, it is likely that the cell line with the given mutations would be sensitive to ABT-737. However, it is important to note that drug sensitivity can vary depending on the specific cell line and experimental conditions, and further experiments may be needed to confirm the sensitivity of this cell line to ABT-737."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CYCLOPAMINE. The drug SMILES structure is C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3(O2)CC[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@]6([C@H]5CC4=C3C)C)O)C)NC1. Drug target is SMO. Drug target pathway is Other.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug CYCLOPAMINE is a SMO inhibitor, and the cell line has a mutation in the TP53 gene, which is a tumor suppressor gene that regulates cell growth and division. The loss of function of TP53 can lead to uncontrolled cell growth and increased sensitivity to drugs that target the Hedgehog signaling pathway, which is regulated by SMO. Therefore, the cell line with the given mutations is likely to be sensitive to CYCLOPAMINE."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is EHT-1864. The drug SMILES structure is C1COCCN1CC2=CC(=O)C(=CO2)OCCCCCSC3=C4C=CC(=CC4=NC=C3)C(F)(F)F.Cl.Cl. Drug target is RAC1, RAC2, RAC3. Drug target pathway is Cytoskeleton.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug EHT-1864 targets the RAC1, RAC2, and RAC3 proteins, which are involved in the cytoskeleton pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. These mutations do not directly affect the RAC1, RAC2, and RAC3 proteins or their interaction with the drug. Therefore, the drug is likely to be effective in this cell line, and the sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TENIPOSIDE. The drug SMILES structure is COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug teniposide is a topoisomerase II inhibitor, which works by interfering with the activity of the enzyme topoisomerase II, leading to DNA damage and cell death. The cell line has mutations in several genes involved in cell signaling and regulation, including NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. However, none of these mutations are known to directly affect the activity of topoisomerase II, and therefore, the drug is likely to be effective against the cell line."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is XAV-939. The drug SMILES structure is C1CSCC2=C1N=C(NC2=O)C3=CC=C(C=C3)C(F)(F)F. Drug target is TNKS1, TNKS2. Drug target pathway is WNT signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: XAV-939 is a small molecule inhibitor of TNKS1 and TNKS2, which are involved in the WNT signaling pathway. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not affect the WNT signaling pathway directly. Therefore, the drug should still be effective in inhibiting the WNT signaling pathway in this cell line, making it sensitive to XAV-939."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DACOMITINIB. The drug SMILES structure is COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: Dacomitinib is a pan-Notch inhibitor, which means it inhibits all four Notch receptors (Notch1-4). The cell line has mutations in NOTCH1 and NOTCH3, which are likely to make the cells more dependent on the Notch signaling pathway. Inhibition of Notch signaling by dacomitinib would therefore be more effective in inhibiting the growth of these cells. Additionally, the cell line has a mutation in TP53, which is a tumor suppressor gene that regulates cell cycle and apoptosis. Dacomitinib may be more effective in inhibiting the growth of cells with TP53 mutations, as these cells may be more dependent on the Notch signaling pathway for survival. Overall, based on the drug target and the mutations present in the cell line, it is likely that dacomitinib would be effective in inhibiting the growth of this cell line."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AT-7519. The drug SMILES structure is C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl. Drug target is CDK1, CDK2, CDK4, CDK6, CDK9. Drug target pathway is Cell cycle.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug AT-7519 targets CDK1, CDK2, CDK4, CDK6, and CDK9, which are all involved in the cell cycle pathway. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not directly affect the CDKs or the cell cycle pathway. Therefore, the drug should still be effective in inhibiting the CDKs and disrupting the cell cycle, leading to cell death in this cell line."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is MPS-1-IN-1. The drug SMILES structure is CC(C)S(=O)(=O)C1=CC=CC=C1NC2=CC(=NC3=C2C=CN3)NC4=C(C=C(C=C4)N5CCC(CC5)O)OC. Drug target is MPS1. Drug target pathway is Mitosis.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug MPS-1-IN-1 targets MPS1, which is involved in the mitosis pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. These genes are not directly related to the mitosis pathway, and therefore, the drug should still be effective in inhibiting MPS1 and inducing cell death in this cell line."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BMS-345541. The drug SMILES structure is CC1=CC2=C(C=C1)N=C(C3=NC=C(N23)C)NCCN. Drug target is IKK1, IKK2. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug BMS-345541 is a small molecule inhibitor of IKK1 and IKK2, which are key kinases in the NF-κB signaling pathway. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, do not directly affect the IKK1/IKK2-NF-κB pathway. Therefore, the drug should still be effective in inhibiting the IKK1/IKK2 activity and suppressing the NF-κB signaling pathway in this cell line, leading to sensitive drug sensitivity."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SB-525334. The drug SMILES structure is CC1=NC(=CC=C1)C2=C(N=C(N2)C(C)(C)C)C3=CC4=NC=CN=C4C=C3. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug SB-525334 is a small molecule inhibitor of the Notch signaling pathway, which is involved in various cellular processes such as cell fate determination, cell proliferation, and differentiation. The NOTCH1 and NOTCH3 mutations in the cell line suggest that the Notch signaling pathway is activated, and therefore, the drug is likely to be effective in inhibiting the pathway and reducing cell proliferation. Additionally, the PIK3R1 and PPP2R1A mutations suggest that the PI3K/Akt signaling pathway is also activated, which can enhance the sensitivity of the cell line to the drug. The TP53 mutation may also contribute to the sensitivity of the cell line to the drug, as it can lead to increased proliferation and reduced apoptosis. The TSC2 and WHSC1L1 mutations may also play a role in the drug sensitivity, but their exact contributions are not clear. Overall, based on the available information, it is likely that the cell line with these mutations would be sensitive to the drug SB-525334."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KOBE2602. The drug SMILES structure is C1=CC(=CC=C1NC(=S)NNC2=C(C=C(C=C2[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-])F. Drug target is RAS effector. Drug target pathway is RTK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug KOBE2602 targets the RAS effector and inhibits the RTK signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1. These mutations are involved in various cellular processes, including cell proliferation, differentiation, and survival. However, none of these mutations directly affect the RAS effector or the RTK signaling pathway, which is the target of KOBE2602. Therefore, the drug is likely to be effective in inhibiting the RTK signaling pathway and sensitive in this cell line."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CAP-232, TT-232, TLN-232. The drug SMILES structure is CC(C(C(=O)N)NC(=O)C1CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)O. Drug target is Glycolysis. Drug target pathway is Metabolism.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug CAP-232, TT-232, TLN-232 is a glycolysis inhibitor that targets the Glycolysis pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. These mutations are associated with cancer and have been shown to promote glycolysis. Inhibition of glycolysis by CAP-232, TT-232, TLN-232 would likely be effective in this cell line due to the increased reliance on glycolysis for energy production. Therefore, the drug sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GSK429286A. The drug SMILES structure is CC1=C(C(CC(=O)N1)C2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=C(C=C4C(=C3)C=NN4)F. Drug target is ROCK1, ROCK2. Drug target pathway is Cytoskeleton.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug GSK429286A is a ROCK inhibitor, which targets the ROCK1 and ROCK2 proteins. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. Among these genes, NOTCH1 and TP53 are known to be involved in the regulation of cell proliferation and survival, while PIK3R1 and PPP2R1A are involved in the PI3K/Akt signaling pathway. However, none of these genes are directly related to the ROCK1/2 pathway. Therefore, it is likely that the cell line is still sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JNJ-38877605. The drug SMILES structure is CN1C=C(C=N1)C2=NN3C(=NN=C3C(C4=CC5=C(C=C4)N=CC=C5)(F)F)C=C2. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug JNJ-38877605 is a small molecule inhibitor of the protein-protein interaction between the retinoblastoma protein (Rb) and oncoproteins such as SV40 large T antigen and human papillomavirus (HPV) E7. The binding of the drug to Rb leads to the inhibition of the G1/S checkpoint and cell cycle progression. The cell line with mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes may have altered cellular signaling pathways that could affect the drug's activity. However, the drug's mechanism of action is independent of these genes, and therefore, the drug is likely to be effective in this cell line. Therefore, the drug sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is EX-527. The drug SMILES structure is C1CC(C2=C(C1)C3=C(N2)C=CC(=C3)Cl)C(=O)N. Drug target is SIRT1. Drug target pathway is Chromatin histone acetylation.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug EX-527 is a SIRT1 inhibitor, which is a histone deacetylase that plays a role in chromatin remodeling and transcriptional regulation. The mutations in the cell line, NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, are all involved in various cellular processes, including cell signaling, proliferation, and survival. However, none of these mutations directly affect the drug target SIRT1 or its downstream signaling pathways. Therefore, the drug is likely to be effective in this cell line, and the sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is QL-XII-47. The drug SMILES structure is CN1C=C(C=N1)C2=CC3=C4C(=CN=C3C=C2)C=CC(=O)N4C5=CC6=C(CCN6C(=O)C=C)C=C5. Drug target is BTK, BMX. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug QL-XII-47 is a BTK inhibitor, which targets the B-cell receptor signaling pathway. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 genes. Among these genes, NOTCH1 and NOTCH3 are involved in the Notch signaling pathway, which is a key regulator of B-cell development and activation. PIK3R1 and PPP2R1A are involved in the PI3K/AKT signaling pathway, which is downstream of the B-cell receptor signaling pathway. TP53 is a tumor suppressor gene that regulates cell cycle and apoptosis. TSC2 is involved in the mTOR signaling pathway, which is also downstream of the B-cell receptor signaling pathway. WHSC1L1 is involved in the histone modification and chromatin remodeling pathway.

Given the mutations in the cell line, it is likely that the B-cell receptor signaling pathway is hyperactivated, which would make the cells more sensitive to a BTK inhibitor like QL-XII-47. Therefore, the drug sensitivity of QL-XII-47 on this cell line is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TEMSIROLIMUS. The drug SMILES structure is CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC. Drug target is MTOR. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug TEMSIROLIMUS is an inhibitor of the mTOR pathway, which is downstream of the PI3K pathway. The cell line has a mutation in PIK3R1, which is a negative regulator of the PI3K pathway. Therefore, the cell line is likely to be sensitive to TEMSIROLIMUS as the inhibition of mTOR will not be compensated by the mutated PIK3R1. Additionally, the cell line has a mutation in TSC2, which is a negative regulator of mTOR. The mutation in TSC2 is likely to increase the sensitivity of the cell line to TEMSIROLIMUS."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KRAS (G12C) INHIBITOR-12. The drug SMILES structure is C=CC(=O)N1CCN(CC1)C(=O)CNC2=CC(=C(C=C2O)Cl)I. Drug target is KRAS (G12C). Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug KRAS (G12C) INHIBITOR-12 targets the KRAS (G12C) mutation, which is present in the cell line. The drug inhibits the activity of KRAS (G12C), which is downstream of NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1 in the ERK MAPK signaling pathway. Inhibition of KRAS (G12C) will reduce the activity of the downstream proteins, including those with mutations, and therefore, the cell line with these mutations will be sensitive to the drug."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TALAZOPARIB. The drug SMILES structure is CN1C(=NC=N1)[C@@H]2[C@H](N=C3C=C(C=C4C3=C2NNC4=O)F)C5=CC=C(C=C5)F. Drug target is PARP1, PARP2. Drug target pathway is Genome integrity.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: Talazoparib is a PARP inhibitor that targets PARP1 and PARP2, which are involved in DNA repair and genomic integrity. The cell line has mutations in NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, and WHSC1L1, which are genes involved in various cellular processes, including cell signaling, proliferation, and DNA repair. However, none of these mutations directly affect the PARP1 or PARP2 genes or their protein products, which are the targets of Talazoparib. Therefore, the drug is likely to be effective in this cell line, and the sensitivity is predicted to be Sensitive."
ACH-000001,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TG-101348. The drug SMILES structure is CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4. Drug target is JAK2. Drug target pathway is Other, kinases.
The mutations of the cell line are NOTCH1, NOTCH3, PIK3R1, PPP2R1A, TP53, TSC2, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Reasoning:?

Answer: Sensitive.
Reasoning: The drug TG-101348 is a JAK2 inhibitor, and the cell line has a mutation in the TP53 gene, which is a tumor suppressor gene that regulates cell growth and division. The mutation in TP53 can lead to uncontrolled cell growth and division, making the cell line more sensitive to the drug. Additionally, the cell line has a mutation in the PIK3R1 gene, which is involved in the PI3K/Akt signaling pathway, and the drug TG-101348 inhibits the JAK2 protein, which is downstream of the PI3K/Akt pathway. Therefore, the cell line with these mutations is likely to be sensitive to the drug."
